US · IMNM
Immunome, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Bothell, PA 19341
- Website
- immunome.com
Price · as of 2024-12-31
$22.73
Market cap 2B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $50.62 | +122.7% |
| Intrinsic Value(DCF) | $3.74 | -83.55% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $129.51 | +469.75% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $29.20 | ||||
| 2021 | $3.93 | ||||
| 2022 | $4.31 | ||||
| 2023 | $26.62 | ||||
| 2024 | $9.34 | $50.62 | $0.00 | $0.00 | $129.50 |
AI valuation
Our deep-learning model estimates Immunome, Inc.'s (IMNM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $50.62
- Current price
- $22.73
- AI upside
- +122.7%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.74
-83.55% upside
Graham-Dodd
—
— upside
Graham Formula
$129.51
+469.75% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IMNM | Immunome, Inc. | $22.73 | 2B | +123% | -84% | — | +470% | -1.87 | 3.02 | 60.58 | -2.21 | — | 3.02 | 100.00% | -3382.37% | -3240.38% | -194.63% | 1276.40% | -150.71% | 0.03 | — | 4.08 | 4.00 | 0.92 | -706.00% | -3550.00% | 185621.00% | -30.00% | -2.04 | 685.79% | 0.00% | 0.00% | 7.58% | -1.10 | -2.04 | 37.08 | -0.77 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| CLDX | Celldex Therapeutics, Inc… | $30.09 | 2B | +2% | -54% | — | +767% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| MAZE | Maze Therapeutics, Inc. | $45.59 | 2.19B | — | -84% | -77% | — | 10.06 | 2.67 | 3.14 | 5.84 | — | 2.67 | 100.00% | 34.38% | 31.18% | 50.47% | 196.80% | 33.48% | 0.14 | — | 9.76 | 9.52 | -2.80 | -10339.00% | — | -18572.00% | 14.23% | 3.67 | 261.38% | 0.00% | 0.00% | 36.28% | 6.17 | 4.75 | 2.12 | 7.53 |
| NTLA | Intellia Therapeutics, In… | $13.78 | 1.6B | +45% | -49% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| PHVS | Pharvaris N.V. | $28.39 | 1.84B | — | — | — | — | -5.23 | 2.59 | — | -2.84 | — | 2.59 | 0.00% | — | — | -40.62% | 1529.52% | -38.37% | 0.00 | — | 12.60 | 12.35 | 1.92 | -570.00% | — | 2956.00% | -17.42% | -5.23 | 1266.85% | 0.00% | 0.00% | 0.00% | -2.83 | -3.42 | — | 15.12 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| UPB | Upstream Bio, Inc. | $7.68 | 415.02M | +226% | +2% | -60% | — | -7.31 | 0.98 | 193.67 | 0.12 | -17.44 | 0.98 | 100.00% | -3281.18% | -2650.04% | -36.23% | 67.14% | -20.97% | 0.00 | — | 44.63 | 43.93 | 4.17 | 4190.00% | -42.00% | 5677.00% | -13.00% | -5.51 | 51.53% | 0.00% | 0.00% | 64.98% | 0.12 | 0.16 | -4.06 | 23.29 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
| ZBIO | Zenas BioPharma, Inc. | $26.35 | 1.1B | -12% | -81% | — | +1,012% | -1.98 | 1.00 | 62.26 | 0.23 | -0.69 | 1.00 | -2682.78% | -3277.76% | -3139.76% | -361.99% | 109.71% | -71.66% | 0.00 | — | 6.21 | 6.12 | 1.95 | 28763.00% | -9000.00% | 29221.00% | -38.49% | -2.09 | 80.20% | 0.00% | 0.00% | 90.91% | 0.23 | 0.32 | -7.69 | 1.30 |
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
- CEO
- Clay Siegall
- Employees
- 131
- Beta
- 2.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.74 ÷ $22.73) − 1 = -83.55% (DCF, example).